Diphtheria(DTaP) Vaccine, ...
Diphtheria is an acute, toxin-mediated disease caused by bacteria called Corynebacterium Diphtheriae. It lives in the mouth, throat, and nose of an infected person and can be spread to others by coughing or sneezing. A child with diphtheria can infect others for 2 to 4 weeks. The incubation period of diphtheria is 2–5 days (range, 1–10 days). Depending on the site of disease Diphtheria can be of following types...
For the purpose of primary immunization, it is recommended that 3 doses each of 0.5 ml should be inoculated on 3 separate occasions at 4 weeks interval.
The first dose should be given at approximately 6 weeks of age. Although it is recommended that immunization be started at 6 weeks, if for any reason it is delayed, the same schedule may be used up to the sixth birthday. Also in News: Govt launched 5-in-1 pentavalent vaccine replacing DPT vaccine.
DPT vaccine should be administered by deep intramuscular injection. The preferred site for injection is the anterolateral aspect of the upper thigh. Only sterile needles and syringes should be used for each injection. The vaccine should be well shaken before use. Each injection of the primary immunization series should be made into a different site with a sterile disposable syringe and needle.
Shake the ampoule to disperse the contents thoroughly immediately before withdrawing the dose. Tap the ampoule to ensure that the solution is in the lower portion rather than in the neck of the ampoule. Wipe the neck of the ampoule with a suitable antiseptic using a sterile piece of cotton break off the top of the ampoule at the constriction by thumb pressure.
Do not remove the rubber stopper from the vial. Take care of the suggestion given below...
|
Mild local reactions consisting of erythema, pain, and tenderness, swelling, and induration at the injection site are common, usually self-limited and subside without treatment. Persistent nodules at the site of injection have occurred following the use of an adsorbed vaccine, but this complication is unusual. Abscess at the site of injection has been reported (6-10 per million doses).
Mild to moderate systemic reactions occur frequently following injections of this vaccine. These usually consist of one or more of the following symptoms and signs: temperature elevation 38°C, drowsiness, fretfulness, anorexia, vomiting, and irritability, persistent or unusual crying. These symptoms are most frequent during the first 24 hours following vaccine injection and may persist for one to two days. The following adverse reactions high fever (40.5°C), collapse, screaming episodes, convulsions, signs of encephalopathy which can be serious and, occasionally fatal have been reported following administration of preparations containing pertussis vaccine. The incidence of these reactions is unknown, but they seem to be exceedingly rare, if any of these reactions occur, further immunization against pertussis is contraindicated.
Sudden-infant-death-syndrome (SIDS) has been reported following the administration of a vaccine containing diphtheria, tetanus toxoids and Pertussis vaccine. The significance of these reports is not clear. It should be borne in mind that the three primary immunizing doses of these vaccines are usually administered to infants between the age of 6 weeks and 6 months and that approximately 85% of SIDS cases occur in the period from one to six months of age with the peak incidence at age two to four months.
DPT Vaccine (Adsorbed) should not be administered to infants or children with high fever, or other evidence of acute illness or infection. The presence of an evolving or changing neurological disorder is a contraindication to receipt of this vaccine. While data to support exclusion of pertussis immunization because of a family history of convulsive or other neurological disorders are scarce, a personal or family history of central nervous system disease or convulsions is considered a contraindication to use of this vaccine. Occurrence of any of the following signs, symptoms or conditions following administration is a contraindication to further use of this product and or pertussis vaccine as the single antigen: fever over 40°C (104°F); convulsion(s) with or without accompanying fever; alterations of consciousness; focal neurologic signs; screaming episodes; shock; collapse; thrombocytopenia purpura.
Individuals receiving corticosteroids or other immunosuppressive drugs may not develop an optimum immunologic response. This product should be used only for infants and children from 6 weeks through six years of age. The possibility of allergic reactions in individuals sensitive to the components of the vaccine should be borne in mind. Adrenaline injection (1:1000) should be kept ready for immediate use in case an anaphylactic or acute hypersensitivity reaction occurs. Frequent booster doses of tetanus toxoids in the presence of adequate or excessive serum levels of tetanus antitoxin have been associated with increased incidence and severity of reactions and should be avoided. If hypersensitivity to the diphtheria component is suspected, tetanus toxoids should be used for reinforcing doses.
A separate sterile syringe and needle should be used for each individual patient to prevent the transmission of hepatitis or other infectious agents.
Each diphtheria vaccine dose of 0.5 ml contains...
| 25 Lf. |
| 5 Lf. |
| 4 IU |
| 1.5 mg. |
| 0.01% as a preservative. |
Diphtheria can initially cause a sore throat, fever, and chills. But if it is not properly diagnosed and treated it produces a toxin (poison) that can cause serious complications such as heart failure or paralysis. About 1 person out of 10 who get diphtheria dies from it.
NOTE: Diphtheria, Tetanus, and Pertussis Vaccine (Adsorbed) are supplied, ready for use, in rubber-stoppered multi-dose vials, and in single-dose glass ampoules.
Disclaimer Note: This blog is for information sharing only & in no way of a prescriptive nature. Parents should consult the Doctor before opting out for any vaccination for their child at all times.
Be the first to support
Be the first to share
Comment (0)